Stocks On Radar: Esperion Therapeutics Inc (NASDAQ:ESPR); The Female Health Company (NASDAQ:FHCOO); RealD (NYSE:RLD)
Dallas, Texas, 10/03/2014 (ustrademedia) – Drug maker Esperion Therapeutics Inc (NASDAQ:ESPR) stock’s Market Outperform tag, was reiterated by analyst firm JMP Securities on 2nd October. JMP analysts also increased the price target on the shares to $53 from previous recommendation of $34. The upward revision of the price target follows one day after the biotech firm announced data from phase 2 tests conducted on its its cholesterol treating drug candidate ETC-1002. The clinical test data were significantly better in comparison to competitive offerings from the likes of Merck. Analyst Jason N. Butler of JMP has opined that the test drug has demonstrated effective “efficacy and safety results.” He then goes on to estimate that the test drug has demonstrated “increased probabilities of success” at this stage.
The Female Health Company (NASDAQ:FHCOO) announced on 2nd October the preliminary sales figures from its fourth quarter operations which ended on September 30, 2014. The maker of female contraceptives announced that it would be likely to report sales of nearly 9.7 million units for the quarter. This would translate into a 15 percent increase over same quarter last year sales figures. Company President and CEO Karen King pointed out that through the rest of the fiscal, focus would be centred on increasing sales of FC2 in the U.S market.
3D technology solutions provider RealD (NYSE:RLD) saw big demand for its shares in the market on 2nd October, after institutional investor Starboard Value LP announced that it has made a offer to take the firm private. The offer was made public on 1st October. Starboard had made a $540 million mid to buyout full control in the tech firm. The offer translates to a 29 percent premium over RealD (NYSE:RLD) 1st October close price. The latest offer comes on the back of the 3D tech firm reporting profits for the first time last quarter, after seven straight quarters of losses.